References
- Alberg AJ, Brock MV, Ford JG, et al (2013). Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: american college of chest physicians evidence-based clinical practice guidelines. Chest, 143, 1-29. https://doi.org/10.1378/chest.12-2762
- Chen H, Xu C, Jin Q, et al (2014). S100 protein family in human cancer. Am J Cancer Res, 4, 89-115.
- Choi KS, Fogg DK, Yoon CS, et al (2003). p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. FASEB J, 17, 235-46. https://doi.org/10.1096/fj.02-0697com
- Domoto T, Miyama Y, Suzuki H, et al (2007). Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci, 98, 77-82. https://doi.org/10.1111/j.1349-7006.2006.00355.x
- Donato R (2001). S100: a multigenic family of calciummodulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol, 33, 637-68. https://doi.org/10.1016/S1357-2725(01)00046-2
- Godier A, Hunt BJ (2013). Plasminogen receptors and their role in the pathogenesis of inflammatory, autoimmune and malignant disease. J Thromb Haemost, 11, 26-34. https://doi.org/10.1111/jth.12064
- Goldstraw P, Crowley J, Chansky K, et al (2007). The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol, 2, 706-14. https://doi.org/10.1097/JTO.0b013e31812f3c1a
- Hedhli N, Falcone DJ, Huang B, et al (2012). The annexin A2/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol, 2012, 406273.
- Hsu SY, Kaipia A, Zhu L, et al (1997). Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11. Mol Endocrinol, 11, 1858-67.
- Ito Y, Arai K, Nozawa R, et al (2007). S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. Anticancer Res, 27, 2679-83.
- Kawai H, Minamiya Y, Takahashi N (2011). Prognostic impact of S100A9 overexpression in non-small cell lung cancer. Tumour Biol, 32, 641-6. https://doi.org/10.1007/s13277-011-0163-8
- Kobayashi S, Boggon TJ, Dayaram T, et al (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 352, 786-92. https://doi.org/10.1056/NEJMoa044238
- Liu Y, Myrvang HK, Dekker LV, et al (2015). Annexin A2 complexes with S100 proteins: structure, function and pharmacological manipulation. Br J Pharmacol, 172, 1664-76. https://doi.org/10.1111/bph.12978
- Madureira PA, O'Connell PA, Surette AP, et al (2012). The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis. J Biomed Biotechnol, 2012, 353687.
- Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43. https://doi.org/10.1016/S1470-2045(01)00486-7
- Phipps KD, Surette AP, O'Connell PA, et al (2011). Plasminogen receptor S100A10 is essential for the migration of tumorpromoting macrophages into tumor sites. Cancer Res, 71, 6676-83. https://doi.org/10.1158/0008-5472.CAN-11-1748
- Sayeed S, Asano E, Ito S, et al (2013). S100A10 is required for the organization of actin stress fibers and promotion of cell spreading. Mol Cell Biochem, 374, 105-11. https://doi.org/10.1007/s11010-012-1509-2
- Shang J, Zhang Z, Song W, et al (2013). S100A10 as a novel biomarker in colorectal cancer. Tumour Biol, 34, 3785-90. https://doi.org/10.1007/s13277-013-0962-1
- Surette AP, Madureira PA, Phipps KD, et al (2011). Regulation of fibrinolysis by S100A10 in vivo. Blood, 118, 3172-81. https://doi.org/10.1182/blood-2011-05-353482
- Tan Y, Ma SY, Wang FQ, et al (2011). Proteomic-based analysis for identification of potential serum biomarkers in gallbladder cancer. Oncol Rep, 26, 853-9.
- Travis WD, Coby TV, Corrin B, et al (1999). World health organization international histological classification of tumors; histological typing of lung and pleural tumors. Springer.
- Tsuna M, Kageyama S, Fukuoka J, et al (2009). Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma. Anticancer Res, 29, 2547-54.
- Wang H, Zhang Z, Li R, et al (2005). Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. Int J Cancer, 116, 285-90. https://doi.org/10.1002/ijc.21035
- Yoshino I, Yoshida S, Miyaoka E, et al (2012). Surgical outcome of stage IIIA- cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004. J Thorac Oncol, 7, 850-5. https://doi.org/10.1097/JTO.0b013e31824c945b
- Zhang L, Fogg DK, Waisman DM (2004). RNA interferencemediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells. J Biol Chem, 279, 2053-62. https://doi.org/10.1074/jbc.M310357200
Cited by
- Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival vol.114, pp.28, 2017, https://doi.org/10.1073/pnas.1707054114
- A pathology atlas of the human cancer transcriptome vol.357, pp.6352, 2017, https://doi.org/10.1126/science.aan2507
- Prognostic Roles of mRNA Expression of S100 in Non-Small-Cell Lung Cancer vol.2018, pp.2314-6141, 2018, https://doi.org/10.1155/2018/9815806
- CPT1A-mediated succinylation of S100A10 increases human gastric cancer invasion pp.15821838, 2018, https://doi.org/10.1111/jcmm.13920
- iTRAQ-based proteomic analysis of DMH-induced colorectal cancer in mice reveals the expressions of β-catenin, decorin, septin-7, and S100A10 expression in 53 cases of human hereditary polyposis colorectal cancer pp.1699-3055, 2018, https://doi.org/10.1007/s12094-018-1912-6